Aecom vs Smith & Nephew plc — how do they compare? Aecom trades at $61.25 (market cap $8.62B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| ACM | SNN | |
|---|---|---|
Market Cap | $8.62B | $12.54B |
Sector | Industrials | Health |
52-Week High | $134.35 | $38.70 |
52-Week Low | $66.86 | $28.73 |
Enterprise Value | $10.81B | $15.57B |
Dividend Yield | 1.77% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 16.73% to $61.04 amid a Q2 2026 earnings miss, reporting a loss of $0.50 per share versus expectations of $1.46. Despite the recent setback, the company maintains strong analyst support with a 64% buy rating and $88.25 consensus price target. Technical indicators show bearish momentum with the stock trading near key support levels, while fundamentals reveal mixed performance with positive revenue growth but negative ROE and ROA metrics.
The outlook remains cautiously optimistic given the significant analyst upside potential, though investors face near-term volatility from project execution challenges and ongoing securities investigation. Long-term infrastructure demand provides growth tailwinds, but recent earnings volatility and negative profitability ratios warrant careful monitoring of operational improvements.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Trailing returns across standard periods
Latest headlines on both assets
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →